Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 15 December 2007, Vol. 110, No. 13, pp. 4385-4395.
Prepublished online as a Blood First Edition Paper on August 28, 2007; DOI 10.1182/blood-2007-03-082404.


This Article
Right arrow Full Text (PDF)
Right arrow Supplemental Tables
Right arrow All Versions of this Article:
blood-2007-03-082404v1
110/13/4385    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Haase, D.
Right arrow Articles by Steidl, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Haase, D.
Right arrow Articles by Steidl, C.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Next Article next article arrow

Submitted March 29, 2007
Accepted July 19, 2007

New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients

Detlef Haase*, Ulrich Germing, Julie Schanz, Michael Pfeilstocker, Thomas Nosslinger, Barbara Hildebrandt, Andrea Kundgen, Michael Lubbert, Regina Kunzmann, Aristoteles A.N. Giagounidis, Carlo Aul, Lorenz Trumper, Otto Krieger, Reinhard Stauder, Thomas H. Muller, Friedrich Wimazal, Peter Valent, Christa Fonatsch, and Christian Steidl

Department of Hematology and Oncology, University of Gottingen, Gottingen, Germany
Department of Hematology and Oncology, University of Dusseldorf, Dusseldorf, Germany
3rd Medical Department for Hematology and Oncology, and L. Boltzmann Institute for Leukemia Research and Hematology, Hanusch Hospital, Vienna, Austria
Department of Hematology and Oncology, University of Freiburg, Freiburg, Germany
Department of Hematology and Oncology, Johannes Hospital, Duisburg, Germany
Department of Hematology and Oncology, Elisabethinen Hospital, Linz, Austria
Department of Hematology and Oncology, Medical University of Innsbruck, Innsbruck, Austria
Institute of Biostatistics, University of Munich, Munich, Germany
Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria

* Corresponding author; email: haase.onkologie{at}med.uni-goettingen.de.

We have generated a large, unique database that includes morphologic, cytogenetic, and follow-up data from 2124 patients with MDS at 4 institutions in Austria and 4 in Germany. Cytogenetic analyses were successfully performed in 2072 patients (97.6%), revealing clonal abnormalities in 1084 (52.3%). Numerical and structural chromosomal abnormalities were documented for each patient and subdivided further according to the number of additional abnormalities. The impact of the karyotype on the natural course of the disease was studied in 1286 patients treated with supportive care only. Median survival was 53.4 months for patients with normal karyotypes (n = 612) and 8.7 months for those with complex anomalies (n = 166). Thirteen rare abnormalities were identified with good [+1/+1q, t(1q), t(7q), 9q-, 12p-, chromosome 15 anomalies, t(17q), monosomy 21, trisomy 21, –X], intermediate (11q-, chromosome 19 anomalies), or poor [t(5q)] prognostic impact, respectively. For all World Health Organization (WHO) and French-American-British (FAB) classification system subtypes, the karyotype provided additional prognostic information. Our analyses offer new insights into the prognostic significance of rare chromosomal abnormalities and specific karyotypic combinations in MDS.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
haematolHome page
M. Mallo, L. Arenillas, B. Espinet, M. Salido, J. M{a} Hernandez, E. Lumbreras, M. del Rey, E. Arranz, S. Ramiro, P. Font, et al.
Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q-
Haematologica, July 1, 2008; 93(7): 1001 - 1008.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020